Skip to main content
Intra-Cellular gets positive FDA feedback on rolling NDA for schizophrenia drug

The FDA and Intra-Cellular Therapies have reached an agreement on the proposed content and timing of a rolling new drug application submission for lumateperone, which is indicated to treat patients with schizophrenia. Intra-Cellular expects to complete the filing by midyear.

Full Story: